Paracrine-endocrine FGF chimeras as potent therapeutics for metabolic diseases

BACKGROUND: The development of a clinically useful fibroblast growth factor 21 (FGF21) hormone has been impeded by its inherent instability and weak FGF receptor (FGFR) binding affinity. There is an urgent need for innovative approaches to overcome these limitations. METHODS: We devised a structure-...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:EBioMedicine
Egile Nagusiak: Zhao, Longwei, Niu, Jianlou, Lin, Huan, Zhao, Jing, Liu, Yang, Song, Zihui, Xiang, Congshang, Wang, Xiaojie, Yang, Yong, Li, Xiaokun, Mohammadi, Moosa, Huang, Zhifeng
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2019
Gaiak:
Research paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6838362/
https://ncbi.nlm.nih.gov/pubmed/31631034
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.09.052
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak